Citations

Showing 10 of 108162 citations.

Perceived Benefits and Barriers to a Career in Neuroanesthesiology: A Pilot Survey of Anesthesiology Clinicians
Théard, Marie Angèle , Easdown, Jane, Goyal, Keshav , Pasternak, Jeffrey J., Rajan, Shobana

Mayo Clinic

Journal of Neurosurgical Anesthesiology | November 8, 2019 | Volume: 33 | Issue: 2 | Pages: 167-171

10.1097/ana.0000000000000655 | PMID 31702586 Get It

Background: Despite advances in perioperative neuroscience, there is low interest among anesthesiology trainees to pursue subspecialty training in neuroanesthesiology. We conducted a pilot survey to assess attitudes about neuroanesthesiology fellowship training. Materials and Methods: A confidential survey was distributed to an international cohort of anesthesiology attendings and trainees between January 15, 2017 and February 26, 2017. Results: A total of 463 responses were received. Overall, 309 (67%), 30 (6%), 116 (25%), and 8 (2%) of respondents identified themselves as attendings, fellows, residents, and “other,” respectively. In total, 390 (84%) of respondents were from the United States. Individuals typically pursue anesthesiology fellowship training because of interest in the subspecialty, acquisition of a special skill set, and the role of fellowship training in career planning and advancement. Overall, 64% of attendings, 56% of fellows, and 55% of residents favored accreditation of neuroanesthesiology fellowships, although opinion was divided regarding the role of accreditation in increasing interest in the specialty. Respondents believe that increased opportunities for research and greater exposure to neurocritical care and neurological monitoring methods would increase interest in neuroanesthesiology fellowship training. Perceived barriers to neuroanesthesiology fellowship training were perceptions that residency provides adequate training in neuroanesthesiology, that a unique skill set is not acquired, and that there are limited job opportunities available to those with neuroanesthesiology fellowship training. Conclusions: In this pilot survey, we identified several factors that trainees consider when deciding to undertake subspecialty training and barriers that might limit interest in pursuing neuroanesthesiology subspecialty training. Our findings may be used to guide curricular development and identify factors that might increase interest among trainees in pursuing neuroanesthesiology fellowship training.
Gastrointestinal: Anterior mediastinal colonic interposition on F‐18 FDG PET/CT imaging
Huynh, Kenneth N. , Nguyen, Ba D. , Nguyen, B D

Mayo Clinic

Journal of Gastroenterology and Hepatology | November 7, 2019 | Volume: 35 | Issue: 6 | Pages: 918-918

10.1111/jgh.14907 | PMID 31698517 Get It

In Response
Rice, Mark J., Brull, Sorin J. , Brull, Sorin J , Zdravković, Marko

Mayo Clinic

Anesthesia & Analgesia | November 7, 2019 | Volume: 132 | Issue: 2 | Pages: e21-e22

10.1213/ane.0000000000004524 | PMID 31702697 Get It

Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity
Crouch, Eric R. , Kraker, Raymond T. , Wallace, David K. , Holmes, Jonathan M. , Repka, Michael X. , Collinge, Janine E., Bremer, Don L., Gray, Michael E. , Smith, Heather , Steinkuller, Paul G., Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | November 7, 2019 | Volume: 138 | Issue: 1 | Pages: 14

10.1001/jamaophthalmol.2019.4488 | PMID 31697304 Get It

Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Bean, Sarah , Bradley, Kristin , Campos, Susana M. , Chon, Hye Sook, Damast, Shari , Dorigo, Oliver , Eifel, Patricia J. , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Han, Ernest , Huh, Warner K. , Lurain, John R., Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Fader, Amanda N. , Remmenga, Steven W., Reynolds, R. Kevin, Sisodia, Rachel, Tillmanns, Todd , Ueda, Stefanie , Wyse, Emily , McMillian, Nicole R., Scavone, Jillian L., Chu, Christina , Cohn, David E. , Crispens, Marta Ann , Mutch, David G.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1374-1391

10.6004/jnccn.2019.0053 | PMID 31693991 Get It

Gestational trophoblastic neoplasia (GTN), a subset of gestational trophoblastic disease (GTD), occurs when tumors develop in the cells that would normally form the placenta during pregnancy. The NCCN Guidelines for Gestational Trophoblastic Neoplasia provides treatment recommendations for various types of GTD including hydatidiform mole, persistent post-molar GTN, low-risk GTN, high-risk GTN, and intermediate trophoblastic tumor.
Reflux-Aspiration in Chronic Lung Disease
Lee, Augustine S. , Lee, Joyce , He, Zhaoping , Ryu, Jay H. , Ryu, Jay H , Lee, Joyce S

Mayo Clinic

Annals of the American Thoracic Society | November 7, 2019 | Volume: 17 | Issue: 2 | Pages: 155-164

10.1513/annalsats.201906-427cme | PMID 31697575 Get It

Abstract Microaspiration, or silent aspiration, is commonly suspected in patients with refractory respiratory symptoms, including unexplained chronic cough, asthma, chronic obstructive pulmonary disease, bronchiolitis, bronchiectasis, and idiopathic pulmonary fibrosis. This suspicion is driven by the high prevalence of gastroesophageal reflux in these otherwise disparate disorders. Frequently, patients receive aggressive treatment for gastroesophageal reflux disease as a means of treating their underlying respiratory conditions, even in the absence of overt symptoms of reflux. However, clinical trials have not demonstrated a clear impact on outcomes with this strategy, and in some instances there may be potential for harm. Mechanistic studies have increasingly used gastric biomarkers obtained directly from the airways to confirm the association between reflux and respiratory disease, but results are limited by methodologic flaws and correlation. The best evidence of aspiration directly causing respiratory disorders is the histopathologic detection of foreign bodies. For most of the other chronic respiratory disorders, microaspiration may be uncommon or a secondary aggravating factor, as in patients with acute exacerbations of chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. In some cases, microaspiration is probably not a significant factor at all, such as in unexplained chronic cough. It is important to distinguish between conditions in which aspiration is primarily or directly causal and conditions in which aspiration may be indirectly aggravating, to help identify whether interventions targeting reflux and aspiration precautions should be recommended to patients. Our clinical review examines some of the evidence supporting reflux-aspiration as a mechanism for several chronic respiratory disorders and offers some management considerations when reflux-aspiration is suspected.
Alemtuzumab, an Immunomodulatory Agent for Multiple Sclerosis, Frequently Induces Thyroid Autoimmunity
Stan, Marius N. , Brito, Juan P.

Mayo Clinic

Clinical Thyroidology | November 7, 2019 | Volume: 31 | Issue: 11 | Pages: 467-469

10.1089/ct.2019;31.467-469 Get It

Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure
Singer, Bridger, Stevens, Ryan W. , Westley, Benjamin , Nicolau, David P. , Stevens, Ryan W

Mayo Clinic

American Journal of Health-System Pharmacy | November 7, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajhp/zxz258 | PMID 31697345 Get It

Abstract Purpose A case of vancomycin enzyme immunoassay (EIA) interference confirmed by high-performance liquid chromatography (HPLC) is described. Summary Therapeutic drug monitoring is standard of practice in vancomycin dosing and monitoring in order to maximize the pharmacodynamic effects and minimize toxicity. After a 52-year-old woman received 5 doses of vancomycin, serum concentrations continued to rise for several days in the absence of ongoing vancomycin administration. Despite persistently elevated vancomycin concentrations, the patient clinically deteriorated and required treatment with an alternative agent. Subsequently, serum concentrations were processed via HPLC and analyzed for percent protein binding. Confirmatory analysis revealed substantially lower concentrations by HPLC than were obtained by EIA and an abnormal elevation in protein binding. After discharge from the index admission, the patient returned 11 months later and had a dectectable vancomycin concentration by EIA prior to receipt of vancomycin. HPLC analysis confirmed the true concentration was undetectable. Though the exact interfering substance was not identified, the above discrepancy in concentrations between the two assay methods indicates the presence of assay interference, and adds to the available literature suggesting similar occurrences. This case is particularly troubling given that the level of interference was not such that it would lead a clinician to immediately suspect interference, and the patient experienced treatment failure. Conclusion Falsely elevated values for serum vancomycin concentration, measured by EIA, contributed to treatment failure in a patient. The substance presumably responsible for EIA interferences was not identified.
In Vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli
Fleischmann, Wim A. , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Patel, Robin

Mayo Clinic

Antimicrobial Agents and Chemotherapy | November 7, 2019 | Volume: 64 | Issue: 2 | Pages: No page available

10.1128/aac.01711-19 | PMID 31712206 Get It

The worldwide spread of multidrug-resistant Enterobacterales is a serious threat to public health. Here, we compared the MICs of plazomicin, amikacin, gentamicin, and tobramycin against 303 multinational multidrug-resistant Gram-negative bacilli. We followed Clinical and Laboratory Standards Institute (CLSI) guidelines and applied CLSI breakpoints as well as those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for amikacin, gentamicin, and tobramycin and of the U.S.
Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population
Durani, Urshila , Asante, Dennis, Hálfdánarson, Þorvarður R. , Heien, Herbert C., Sangaralingham, Lindsey R. , Thompson, Carrie A. , Peethambaram, Prema P. , Sangaralingham, Lindsey, Halfdanarson, Thorvardur R , Durani, Urshila , Quevedo, Fernando , Go, Ronald S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1355-1361

10.6004/jnccn.2019.7315 | PMID 31693982 Get It

Background: Adherence to surveillance guidelines in resected colon cancer has significant implications for patient morbidity, cost of care, and healthcare utilization. This study measured the underuse and overuse of imaging for staging and surveillance in stage I–II colon cancer. Methods: The OptumLabs database was queried for administrative claims data on adult patients with stage I–II colon cancer who underwent surgery alone in 2008 through 2016. Use of PET and CT imaging was evaluated during both initial staging (n=6,921) and surveillance for patients with at least 1 year of follow-up (n=5,466). “High use” was defined as >2 CT abdominal/pelvic (CT A/P) or PET scans per year during surveillance. Results: Overall, 27% of patients with stage I–II colon cancer did not have a staging CT A/P or PET scan and 95% did not have a CT chest scan. However, rates of staging CT A/P and CT chest scans increased from 62.0% (2008) to 74.8% (2016) and from 2.3% (2008) to 7.1% (2016), respectively. Staging PET use was overall very low (5.2%). During surveillance, approximately 30% of patients received a CT A/P or PET and 5% received a CT chest scan within the first year after surgery. Of patients who had surveillance CT A/P or PET scans, the proportion receiving >2 scans within the first year (high use) declined from 32.4% (2008) to 9.6% (2016) (P = .01). Conclusions: Although PET use remains appropriately low, many patients with stage I–II colon cancer do not receive appropriate staging and surveillance CT chest scans. Among those who do receive these scans during surveillance, high use has declined significantly over time.